| アブストラクト | INTRODUCTION: Oral corticosteroids (OCS) are used to manage chronic obstructive pulmonary disease (COPD) exacerbations but are associated with adverse outcomes that may increase healthcare resource utilization and costs. We compared attendance/costs associated with OCS-related adverse outcomes in patients who ever used OCS versus those who never used OCS and examined associations between cumulative OCS exposure and attendance/costs. METHODS: This direct matched observational cohort study used the UK Clinical Practice Research Datalink GOLD database (data range 1987-2019). Patients with a COPD diagnosis on/after April 1, 2003, and Hospital Episode Statistics linkage were included. Emergency room, specialist or primary care outpatient, and inpatient attendance were analyzed. Costs, estimated using Health and Social Care 2019 and National Health Service Reference Costs 2019-2020 reports, were adjusted for sex, age, exacerbation number, and inhaler type used in the 12 months before index date. RESULTS: The OCS cohort had higher annualized disease-specific (excluding respiratory) total attendance/costs versus the non-OCS cohort (adjusted incidence rate ratio [aIRR] with 95% confidence intervals [CIs]) ranging from 37% (1.37 [1.31, 1.43]) for emergency room attendances to 149% (2.49 [2.36, 2.63]) for specialist consultations. Disease-specific (excluding respiratory) attendance/costs increased in a positive dose-response relationship for most attendance categories versus the < 0.5 g reference dose. For the 0.5 to < 1.0 g cumulative dose category, the greatest increases in disease-specific (excluding respiratory) attendance/costs occurred for primary care consultations (aIRR [95% CI] 1.38 [1.32, 1.44]). For the >/= 10 g cumulative dose category, the greatest increases were observed for primary care consultations (aIRR [95% CI] 2.83 [2.66, 3.00]), non-elective long stays (>/= 2 days; 2.54 [2.15, 2.99]), and non-elective short stays (</= 1 day; 2.51 [2.12, 2.98]). Similar findings were observed for all-cause attendance/costs. CONCLUSION: Among patients with COPD, OCS-related adverse outcomes were associated with higher attendance and costs, with a positive dose-response relationship. A graphical abstract is available with this article. |
|---|
| ジャーナル名 | Advances in therapy |
|---|
| Pubmed追加日 | 2024/11/19 |
|---|
| 投稿者 | Tse, Gary; Ariti, Cono; Bafadhel, Mona; Papi, Alberto; Carter, Victoria; Zhou, Jiandong; Skinner, Derek; Xu, Xiao; Mullerova, Hana; Emmanuel, Benjamin; Price, David |
|---|
| 組織名 | Observational and Pragmatic Research Institute, Singapore, Singapore.;School of Nursing and Health Studies, Hong Kong Metropolitan University, Hong;Kong, China.;King's Centre for Lung Health, School of Immunology and Microbial Sciences,;Faculty of Life Sciences and Medicine, King's College London, London, UK.;Respiratory Medicine, Department of Translational Medicine, University of;Ferrara, Ferrara, Italy.;AstraZeneca, Gaithersburg, MD, USA.;AstraZeneca, Cambridge, UK.;dprice@opri.sg.;Centre of Academic Primary Care, Division of Applied Health Sciences, University;of Aberdeen, Aberdeen, UK. dprice@opri.sg. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39560897/ |
|---|
